VFA
HRTX icon

Valeo Financial Advisors’s Heron Therapeutics HRTX Stock Holding History

Valeo Financial Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,697
Closed -$34.7K – 821
2025
Q4 		$34.7K Hold
26,697
– – ﹤0.01% 817
2025
Q3 		$33.6K Buy
26,697
+8,418
+46% +$13.3K ﹤0.01% 811
2025
Q2 		$37.8K Buy
18,279
+127
+0.7% +$259 ﹤0.01% 758
2025
Q1 		$39.9K Buy
18,152
+4,619
+34% +$8.96K ﹤0.01% 673
2024
Q4 		$20.7K Buy
13,533
+615
+5% +$997 ﹤0.01% 734
2024
Q3 		$25.7K Buy
12,918
+171
+1% +$408 ﹤0.01% 697
2024
Q2 		$44.6K Buy
+12,747
New +$39.2K ﹤0.01% 642
2021
Q2 		– Sell
-200
Closed -$3K – 1085
2021
Q1 		$3K Hold
200
– – ﹤0.01% 1705
2020
Q4 		$4K Hold
200
– – ﹤0.01% 1415
2020
Q3 		$3K Sell
200
-68
-25% -$1.06K ﹤0.01% 1346
2020
Q2 		$4K Hold
268
– – ﹤0.01% 1588
2020
Q1 		$4K Hold
268
– – ﹤0.01% 1348
2019
Q4 		$6K Sell
268
-200
-43% -$4.42K ﹤0.01% 1237
2019
Q3 		$9K Buy
468
+18
+4% +$331 ﹤0.01% 1053
2019
Q2 		$8K Buy
450
+5
+1% +$100 ﹤0.01% 1083
2019
Q1 		$11K Buy
445
+245
+123% +$6.41K ﹤0.01% 937
2018
Q4 		$5K Sell
200
-7
-3% -$192 ﹤0.01% 1081
2018
Q3 		$6K Buy
207
+7
+4% +$261 ﹤0.01% 1127
2018
Q2 		$8K Hold
200
– – ﹤0.01% 1008
2018
Q1 		$6K Hold
200
– – ﹤0.01% 1073
2017
Q4 		$4K Hold
200
– – ﹤0.01% 1070
2017
Q3 		$3K Buy
+200
New +$3.14K ﹤0.01% 960

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $2.3B AUM 29.92% 1-Year Est. Return

Valeo Financial Advisors's HRTX Position: Q1 2026 in Review

Valeo Financial Advisors sold out of Heron Therapeutics (HRTX) in Q1 2026, closing a stake of 26,697 shares — an estimated $34.7K sold.

Valeo Financial Advisors first reported a position in HRTX in Q3 2017 and held it in 22 quarters. The position peaked at $44.6K in Q2 2024. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Valeo Financial Advisors reported no remaining Heron Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Valeo Financial Advisors sold 26,697 Heron Therapeutics shares in Q1 2026, an estimated $34.7K.
  • Valeo Financial Advisors first reported a position in Heron Therapeutics in Q3 2017 and held it in 22 quarters.
  • Valeo Financial Advisors's Heron Therapeutics position peaked at $44.6K in Q2 2024.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Valeo Financial Advisors's 13F filing for Q1 2026, filed 8 May 2026.